A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is now the most prevalent form of chronic liver disease, affecting 10%–20% of the general paediatric population. Within the next 10 years it is expected to become the leading cause of liver pathology, liver failure and indication for liver transplantation in childhood and adolescence in the Western world. While our understanding of the pathophysiological mechanisms underlying this disease remains limited, it is thought to be the hepatic manifestation of more widespread metabolic dysfunction and is strongly associated with a number of metabolic risk factors, including insulin resistance, dyslipidaemia, cardiovascular disease and, most significantly, obesity. Despite this, ”paediatric” NAFLD remains under-studied, under-recognised and, potentially, undermanaged. This article will explore and evaluate our current understanding of NAFLD in childhood and adolescence and how it differs from adult NAFLD, in terms of its epidemiology, pathophysiology, natural history, diagnosis and clinical management. Given the current absence of definitive radiological and histopathological diagnostic tests, maintenance of a high clinical suspicion by all members of the multidisciplinary team in primary and specialist care settings remains the most potent of diagnostic tools, enabling early diagnosis and appropriate therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Barlow, S. E., & and the Expert Committee (2007) · Pediatrics · doi:10.1542/peds.2007-2329c · Cited by 4,497
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“Long-term follow-up studies have shown that, in adults, NASH increases overall mortality by 35%–58% compared with age and sex-matched controls, while liver-related mortality is increased 9–10 fold [40–42].”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“Recent research suggests that pioglitazone can improve hepatic steatosis and inflammation, as well as reducing aminotransferase levels and histological evidence of hepatocyte injury in patients with biopsy-proven NASH [24,165,166].”
BackgroundKoliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032 · cited 1×
“Given that, within hepatocytes, reactive oxygen species (ROS) are mostly generated in the mitochondria, some have suggested that, in hepatic steatosis, increased intracellular fatty acid levels may act as an overabundant substrate for mitochondrial malfunctioning, increasing ROS and, downstream, inflammatory cytokine…”
BackgroundHarrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470 · cited 1×
“As such, their use in NAFLD remains controversial [171,172].”
BackgroundStienstra, R., Saudale, F., Duval, C., Keshtkar, S., Groener, J. E. M., van Rooijen, N., Staels, B., Kersten, S., & Müller, M. (2010) · Hepatology · doi:10.1002/hep.23337 · Cited by 452 · cited 1×
“[70] further demonstrated the integral role of Kupffer cells in regulating hepatic triglyceride storage and the promotion of hepatic steatosis via IL-1β-mediated suppression of perioxisome proliferator-activated receptor-α (PPAR-α) activity, while others have reported that Kupffer cell depletion, in a murine experimen…”
BackgroundMetformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
Haukeland, J. W., Konopski, Z., Eggesbø, H. B., von Volkmann, H. L., Raschpichler, G., Bjøro, K., Haaland, T., Løberg, E. M., & Birkeland, K. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902845268 · Cited by 323
Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner, I., Blendis, L., Halpern, Z., & Oren, R. (2008) · Hepatology · doi:10.1002/hep.22525 · Cited by 296
Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats
Yasuda, M., Shimizu, I., Shiba, M., & Ito, S. (1999) · Hepatology · doi:10.1002/hep.510290307 · Cited by 283
Antioxidant supplements and mortality
Bjelakovic, G., Nikolova, D., & Gluud, C. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000009 · Cited by 234
Increased production of sonic hedgehog by ballooned hepatocytes
Rangwala, F., Guy, C. D., Lu, J., Suzuki, A., Burchette, J. L., Abdelmalek, M. F., Chen, W., & Diehl, A. M. (2011) · The Journal of Pathology · doi:10.1002/path.2888 · Cited by 201 · cited 1×
“Others have demonstrated that damaged or ballooned hepatocytes produce Hh ligands in adults with NASH, whose previous levels correlated with numbers of Hh-responsive cells within the liver and the severity of inflammation and fibrosis [103].”
BackgroundSpruss, A., & Bergheim, I. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.05.006 · Cited by 162 · cited 2×
“It may also promote liver injury in NAFLD by causing bacterial overgrowth and increased intestinal permeability, precipitating endotoxemia and subsequent initiation of inflammation but this has yet to be proven [142,143].”
BackgroundHealth‐related fitness and physical activity in patients with nonalcoholic fatty liver disease†‡
Krasnoff, J. B., Painter, P. L., Wallace, J. P., Bass, N. M., & Merriman, R. B. (2008) · Hepatology · doi:10.1002/hep.22137 · Cited by 148 · cited 1×
“Furthermore, the extent of these changes appears, while apparent even in the short-term, to be proportional to the intensity and duration of lifestyle modification [135,138].”
BackgroundMouralidarane, A., Soeda, J., Visconti-Pugmire, C., Samuelsson, A.-M., Pombo, J., Maragkoudaki, X., Butt, A., Saraswati, R., Novelli, M., Fusai, G., et al. (2013) · Hepatology · doi:10.1002/hep.26248 · Cited by 145 · cited 1×
“Increasing evidence suggests that they fulfil many diverse roles in the pathogenesis and progression of NAFLD, including the regulation of immune tolerance and lipid homeostasis [63,69].”
BackgroundSelf-citationBariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments
Sasaki, A., Nitta, H., Otsuka, K., Umemura, A., Baba, S., Obuchi, T., & Wakabayashi, G. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00164 · Cited by 133 · cited 2×
“However, despite a large body of evidence suggesting histological improvement secondary to weight loss in adults, bariatric surgery in NASH patients of any age group remains controversial [11,12,14,19,159].”
BackgroundGLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
Cordero, P., Milagro, F. I., Campion, J., & Martinez, J. A. (2014) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s204017441400035x · Cited by 45 · cited 1×
“In recent years, the critical role of maternal physiology and metabolism during the perinatal, foetal and even pre-conceptual phases of development in predisposing the unborn towards developing NAFLD within their own lifetimes and making it more likely that they will progress to NASH, has become ever more apparent [69…”
BackgroundSelf-citationLoy, J. J., Youn, H. A., Schwack, B., Kurian, M., Ren Fielding, C., & Fielding, G. A. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.11.010 · Cited by 39
Cited by
Zhang, S., Gu, Y., Bian, S., Lu, Z., Zhang, Q., Liu, L., Meng, G., Yao, Z., Wu, H., Wang, Y., et al. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa380 · Cited by 70
Nguyen, V., Li, J., Gan, J., Cordero, P., Ray, S., Solis-Cuevas, A., Khatib, M., & Oben, J. A. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/4697194 · Cited by 28
Self-citationSimulation of Growth Trajectories of Childhood Obesity into Adulthood
Ward, Z. J., Long, M. W., Resch, S. C., Giles, C. M., Cradock, A. L., & Gortmaker, S. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703860 · Cited by 748
Metadata
- Authors
- Temple, J., Cordero, P., Li, J., Nguyen, V., & Oben, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-06-15
- Volume
- 17
- Issue
- 6
- Pages
- 947
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2421224730
- Cited by
- 171
- References
- 22
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.